Position in ESPR
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$4,698
+$4,698 QoQ
Shares Held
1,487
+215.7% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#32
of 40 holders
Holding Since
Jun 2020
12 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ESPR Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026SIGNATUREFD, LLC holds $9,233,784 across 40 Drug Manufacturers - Specialty & Generic names. ESPR ranks #29 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LQDA |
Liquidia Corp
|
30,310 | $2,416,616 | |
| 2 | RDY |
Dr Reddys Laboratories Ltd
|
119,448 | $1,730,801 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
77,725 | $1,245,931 | |
| 4 | HLN |
Haleon plc
|
95,033 | $886,657 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
1,109 | $600,889 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
15,809 | $535,608 | |
| 7 | ZTS |
Zoetis Inc.
|
5,622 | $403,996 | |
| 8 | VTRS |
Viatris Inc
|
19,909 | $316,154 |
All Filings in ESPR
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,698 | 1,487 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | — | 471 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | — | 442 | Shares | Sole | 2026-01-20 | |
| 2024-06-30 | — | 342 | Shares | Sole | 2024-07-29 | |
| 2023-03-31 | — | 1,169 | Shares | Sole | 2023-04-28 | |
| 2022-12-31 | — | 2,885 | Shares | Sole | 2023-01-30 | |
| 2022-09-30 | — | 3,298 | Shares | Sole | 2022-11-08 | |
| 2022-06-30 | — | 2,895 | Shares | Sole | 2022-08-10 | |
| 2022-03-31 | — | 377 | Shares | Sole | 2022-05-02 | |
| 2021-12-31 | — | 884 | Shares | Sole | 2022-01-25 | |
| 2021-09-30 | — | 96 | Shares | Sole | 2021-10-28 | |
| 2020-06-30 | — | 19 | Shares | Sole | 2020-07-30 | |
| No filing history on record for this holder in this stock. | ||||||